Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.

2.50
Hdl Handle:
http://hdl.handle.net/10541/83575
Title:
Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.
Authors:
Eaton, David; Gilham, David E; O'Neill, Alison C; Hawkins, Robert E
Abstract:
The prolonged in vivo survival of genetically modified effector cells is crucial to the success of any (gene-modified) adoptive cellular immunotherapy approach. In cancer clinical trials to date, however, the detection of surviving circulating gene-modified T cells has required highly sensitive techniques. In vitro studies of T cell co-stimulation have shown that up-regulation of the anti-apoptosis gene Bcl-X(L) by ligation of CD28 promotes T cell survival, but not proliferation. Here we have investigated the ability to modulate resistance to apoptosis and improve cell survival by transducing human peripheral blood lymphocytes using a retroviral vector that expresses Bcl-X(L). We show that Jurkat cells transduced with Bcl-X(L) retrovirus were partially resistant to Fas (CD95) antibody-induced apoptosis. Subsequent in vitro assays with transduced primary human lymphocytes demonstrates that over-expression of Bcl-X(L) promotes the survival of lymphocytes cultured in the absence of interleukin-2. Activation-induced apoptosis with anti-CD3(epsilon) antibody, OKT3 is also modulated. Furthermore, Bcl-X(L) over-expression in human lymphocytes delays the onset of apoptosis induced by long-term co-culture with tumour cell lines. Despite this improved in vitro survival, in a preliminary experiment to assess safety, no signs of malignancy or autoimmunity were observed in NOD/SCID mice injected with Bcl-X(L) transduced lymphocytes. These results indicate that expression of Bcl-X(L) in lymphocyte therapy either alone or in conjunction with an additional therapeutic gene could enhance persistence of cells in vivo thereby potentially improving the clinical outcome of adoptive cellular therapy.
Affiliation:
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.
Citation:
Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. 2002, 9 (8):527-35 Gene Ther.
Journal:
Gene Therapy
Issue Date:
Apr-2002
URI:
http://hdl.handle.net/10541/83575
DOI:
10.1038/sj.gt.3301685
PubMed ID:
11948378
Type:
Article
Language:
en
ISSN:
0969-7128
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorEaton, Daviden
dc.contributor.authorGilham, David Een
dc.contributor.authorO'Neill, Alison Cen
dc.contributor.authorHawkins, Robert Een
dc.date.accessioned2009-10-05T15:32:28Z-
dc.date.available2009-10-05T15:32:28Z-
dc.date.issued2002-04-
dc.identifier.citationRetroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. 2002, 9 (8):527-35 Gene Ther.en
dc.identifier.issn0969-7128-
dc.identifier.pmid11948378-
dc.identifier.doi10.1038/sj.gt.3301685-
dc.identifier.urihttp://hdl.handle.net/10541/83575-
dc.description.abstractThe prolonged in vivo survival of genetically modified effector cells is crucial to the success of any (gene-modified) adoptive cellular immunotherapy approach. In cancer clinical trials to date, however, the detection of surviving circulating gene-modified T cells has required highly sensitive techniques. In vitro studies of T cell co-stimulation have shown that up-regulation of the anti-apoptosis gene Bcl-X(L) by ligation of CD28 promotes T cell survival, but not proliferation. Here we have investigated the ability to modulate resistance to apoptosis and improve cell survival by transducing human peripheral blood lymphocytes using a retroviral vector that expresses Bcl-X(L). We show that Jurkat cells transduced with Bcl-X(L) retrovirus were partially resistant to Fas (CD95) antibody-induced apoptosis. Subsequent in vitro assays with transduced primary human lymphocytes demonstrates that over-expression of Bcl-X(L) promotes the survival of lymphocytes cultured in the absence of interleukin-2. Activation-induced apoptosis with anti-CD3(epsilon) antibody, OKT3 is also modulated. Furthermore, Bcl-X(L) over-expression in human lymphocytes delays the onset of apoptosis induced by long-term co-culture with tumour cell lines. Despite this improved in vitro survival, in a preliminary experiment to assess safety, no signs of malignancy or autoimmunity were observed in NOD/SCID mice injected with Bcl-X(L) transduced lymphocytes. These results indicate that expression of Bcl-X(L) in lymphocyte therapy either alone or in conjunction with an additional therapeutic gene could enhance persistence of cells in vivo thereby potentially improving the clinical outcome of adoptive cellular therapy.en
dc.language.isoenen
dc.subject.meshAnimals-
dc.subject.meshApoptosis-
dc.subject.meshCell Survival-
dc.subject.meshFemale-
dc.subject.meshGene Therapy-
dc.subject.meshGenetic Vectors-
dc.subject.meshHumans-
dc.subject.meshImmunotherapy, Adoptive-
dc.subject.meshJurkat Cells-
dc.subject.meshLymphocytes-
dc.subject.meshMice-
dc.subject.meshMice, Inbred NOD-
dc.subject.meshMice, SCID-
dc.subject.meshProto-Oncogene Proteins c-bcl-2-
dc.subject.meshRetroviridae-
dc.subject.meshTransduction, Genetic-
dc.subject.meshbcl-X Protein-
dc.titleRetroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Medical Oncology, Paterson Institute for Cancer Research, University of Manchester, Manchester, UK.en
dc.identifier.journalGene Therapyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.